Oct. 3, 2013
ASTRO 2013 ( Atlanta) –
Accuray Incorporated (Nasdaq: ARAY) announced today that studies presented at the
55th Annual American Society for Radiation Oncology (ASTRO) Meeting
– 25, 2013 continue to reinforce evidence of clinical and quality of life benefits for the CyberKnife® and TomoTherapy® Systems. A variety of indications including prostate, lung, liver, breast and head and neck cancers were represented among the 104 oral and poster presentations, further positioning Accuray as a leader in precise, innovative radiation oncology therapies.
ASTRO 2013 CyberKnife Clinical and Technical Study Summary:
The 43 CyberKnife presentations focused on a range of indications including lung, brain, kidney, and prostate stereotactic body radiation therapy (SBRT), which was the topic of 14 presentations. The emphasis on CyberKnife prostate SBRT was timely, given
ASTRO's recently announced
update to its model policy on SBRT which states that SBRT is an appropriate alternative for select patients with low to intermediate risk disease.
Of particular interest were two[i] prospective Phase II studies which found that the quality of life for patients undergoing CyberKnife SBRT for prostate cancer "compare favorably to published results from radical prostatectomy and intensity-modulated radiation therapy."
One[ii] study of lung SBRT with the CyberKnife System reported lower chest wall maximum dose when lesions were tracked with the
Synchrony Respiratory Tracking System
compared to static or linac-based treatment plans, and another study[iii] showed very low incidence of chest wall pain, a common side effect of lung SBRT for lesions near the chest wall.
Three[iv] treatment planning simulation studies incorporating the multileaf collimator of the new CyberKnife M6™ System found consistent reductions in treatment time for both radiosurgery and IMRT plans, with equivalent or improved plan quality relative to the prior circular collimator plans or IMRT plans generated for other radiotherapy systems.